California Miramar University

Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.

Retrieved on: 
Monday, May 6, 2024
University, Mayo Clinic, Insulin, AbbVie, Skin, Scripps Research, Cosmetics, IDE, Skin care, Research, Patent, UCI, DANA, ATF, Peptide, Harvard Medical School, Marketing, Biology, Wound healing, California Miramar University, Pharmacology, Growth, Medical imaging

DANA POINT, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pacific Software Inc. (“PFSF”) acquired certain assets of Dreamaderm Inc. ("Dreamaderm") through a Plan of Acquisition, dated January 24, 2024.

Key Points: 
  • DANA POINT, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pacific Software Inc. (“PFSF”) acquired certain assets of Dreamaderm Inc. ("Dreamaderm") through a Plan of Acquisition, dated January 24, 2024.
  • PFSF will now be the exclusive holder of a patented, first-in-class cosmeceutical asset, branded as Dermatrix.
  • Dermatrix prevents the breakdown of insulin by blocking the action of insulin-degrading enzyme (IDE), a peptidase that is abundant within the skin.
  • Except as may be required by law, Pacific Software, Inc. undertakes no obligation, and does not intend, to update these forward-looking statements after the date of this release.

Hudson Pacific and Macerich Complete $700 Million Sale of One Westside and Westside Two

Retrieved on: 
Wednesday, January 3, 2024
Commercial Building & Real Estate, Construction & Property, REIT, Westside Pavilion, University, MAC, Multimedia, Sale, California Miramar University, Retail

Hudson Pacific held a 75% interest and Macerich a 25% interest in the joint venture that owned the assets, which total approximately 687,000 square feet.

Key Points: 
  • Hudson Pacific held a 75% interest and Macerich a 25% interest in the joint venture that owned the assets, which total approximately 687,000 square feet.
  • View the full release here: https://www.businesswire.com/news/home/20240103440375/en/
    “The opportunistic sale of One Westside and Westside Two significantly bolsters our balance sheet and we now have no debt maturities until year-end 2025,” said Victor Coleman, Chairman and CEO of Hudson Pacific.
  • This transaction addresses the company’s debt maturities until December 2025, and further strengthens the company’s compliance with its unsecured revolving credit facility covenants as recently amended.
  • Further, the company’s share of net debt to the company’s share of undepreciated book value as of September 30, 2023 proforma for all announced asset sales improved to 35% from 39%.

Royalty Pharma Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023
Acceleration, Net, Pressure, University, Civil service commission, Astellas Pharma, Chronic lymphocytic leukemia, Vertex, Calendar, Aplastic anemia, DPP, GAAP, Leuprorelin, Sale, Ulcerative colitis, Psoriasis, Gilead, EBITDA, Acquisition, European Commission, Patient, Risk, Metastasis, Cystic fibrosis, Growth, Johnson & Johnson, California Miramar University, FDA, Sacituzumab govitecan, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Food, Ivacaftor, Pfizer, Talazoparib, Bank, Video game, Music, Vaccine, Pharmaceutical industry, Real estate, Cryptocurrency, Berotralstat, Apalutamide, Nusinersen, Elexacaftor/tezacaftor/ivacaftor, Adjustment, Guselkumab, Ibrutinib

Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • During the second quarter of 2023, Royalty Pharma began repurchasing its Class A ordinary shares and repurchased approximately four million shares for $134 million.
  • The weighted-average diluted Class A ordinary shares outstanding for the second quarter of 2023 was 606 million as compared to 607 million for the first quarter of 2023.

Zymo Research donates $25,000 to support Center for Virus Research at the University of California, Irvine

Retrieved on: 
Wednesday, June 21, 2023
Vaccine, University, HIV, University of California, Irvine academics, Virology, SARS-CoV-2, Public, Virus, Global health, Research, UCI, Immune system, Economic development, Viral, Faculty, Biology, California Miramar University, Nursing

IRVINE, Calif., June 21, 2023 /PRNewswire/ -- Zymo Research , a leading innovation company for biomedical products and services has donated $25,000 to the Regents of the University of California to support the Center for Virus Research at the University of California, Irvine (UCI).

Key Points: 
  • IRVINE, Calif., June 21, 2023 /PRNewswire/ -- Zymo Research , a leading innovation company for biomedical products and services has donated $25,000 to the Regents of the University of California to support the Center for Virus Research at the University of California, Irvine (UCI).
  • "We are grateful for the generous support from Zymo Research," said Dr. Thomas Lane, Director Center for Virus Research.
  • This year's donation marks another step in Zymo Research's long-standing commitment to support the Center for Virus Research at UCI.
  • The Center for Virus Research at UCI is a leading center for the study of viruses and viral diseases.

Pattern Energy Signs Power Purchase Agreements for Largest Wind Project in U.S. History

Retrieved on: 
Monday, May 15, 2023
Pattern Energy, Regents of the University of California, Partnership, University, Bureau of Land Management, Shell plc, Bureau, Sino-Spanish Association for Energy and Sustainability, Economy, Tax, Consultant, Research, Wind, Carbon, Associate, Lincoln, BLM, School, Sustainability, UC, Professional, Capital program and project management software, Power purchase agreement, California Miramar University, Shell Energy, KV, HVDC, Renewable energy

ALBUQUERQUE, N.M., May 15, 2023 /PRNewswire/ -- Pattern Energy Group LP (Pattern Energy), a leader in renewable energy and transmission infrastructure, announced it has signed long-term Power Purchase Agreements (PPAs) with Shell Energy North America (US), L.P. (Shell Energy) and the Regents of the University of California, for a portion of the power from its 3,500+ MW SunZia Wind project. Construction of SunZia Wind is expected to start later this year and be completed in 2026, when it will start delivering power to western energy markets.

Key Points: 
  • ALBUQUERQUE, N.M., May 15, 2023 /PRNewswire/ -- Pattern Energy Group LP (Pattern Energy), a leader in renewable energy and transmission infrastructure, announced it has signed long-term Power Purchase Agreements (PPAs) with Shell Energy North America (US), L.P. (Shell Energy) and the Regents of the University of California, for a portion of the power from its 3,500+ MW SunZia Wind project.
  • Construction of SunZia Wind is expected to start later this year and be completed in 2026, when it will start delivering power to western energy markets.
  • "This wind contract represents another milestone achievement for the University of California," said David Phillips, Associate Vice President of Capital Programs, Energy and Sustainability.
  • "We welcome these exciting new relationships with Shell Energy and UC Regents on the delivery of New Mexico wind power," said Hunter Armistead, CEO of Pattern Energy.